Multidisciplinary Perspectives of Current Approaches and Clinical Gaps in the Management of Hyperphosphatemia

Abstract

Michel Vallée,1 Jordan Weinstein,2 Marisa Battistella,3 Roxanne Papineau,4 Dianne Moseley,5 Gordon Wong6 1Université de Montréal - Hôpital Maisonneuve-Rosemont, Montréal, Québec, Canada; 2Division of Nephrology, St Michael’s Hospital, University of Toronto, Toronto, Ontario, Canada; 3University Health Network- Toronto General Hospital, Toronto, Ontario, Canada; 4Institut Universitaire de Cardiologie et de Pneumologie de Québec, Québec City, Québec, Canada; 5Trillium Health Partners, Mississauga, Ontario, Canada; 6Trillium Health Partners, Credit Valley Nephrology, Mississauga, Ontario, CanadaCorrespondence: Gordon WongTrillium Health Partners, Credit Valley Nephrology, 2300 Eglinton Ave. West Suite #501, Mississauga, Ontario, L5M 2V8, CanadaEmail [email protected]: Population-based studies have shown that most patients with advanced chronic kidney disease (CKD) do not have optimal phosphate levels. Meta-analyses suggest that there is a morbidity and mortality benefit associated with the lowering of serum phosphate levels. However, to date there is no conclusive evidence from randomized controlled trials (RCTs) that lowering serum phosphate levels reduces the risk of morbidity and mortality. However, hyperphosphatemia may pose a risk to patients and treatment should be considered. We therefore sought to conduct a multidisciplinary review to help guide clinical decision-making pending results of ongoing RCTs. Restricting dietary phosphate intake is frequently the first step in the management of hyperphosphatemia. Important considerations when proposing dietary restriction include the patient’s socioeconomic status, lifestyle, dietary preferences, comorbidities, and nutritional status. While dietary phosphate restriction may be a valid strategy in certain patients, serum phosphate reductions achieved solely by limiting dietary intake are modest and should be considered in conjunction with other interventions. Conventional dialysis is also typically insufficient; however phosphate removal may be augmented by increased frequency or duration of dialysis, or through enhanced methods such as hemodiafiltration. Phosphate binders have been shown to reduce absorption of dietary phosphate and lower serum phosphate levels. There are several phosphate binders available, and while they all lower phosphate levels to variable degrees, they differ with respect to their pill burden, potential to induce or exacerbate vascular calcification or ectopic calcification, tissue accumulation, safety, and tolerability. The widespread treatment of hyperphosphatemia requires convincing data from RCTs to ascertain whether lowering serum phosphate levels improves patient-important outcomes, as well as the optimal method and degree of phosphate control. In the interim, the decision and approach used to treat hyperphosphatemia should be based on the best available data, as well as patient needs and clinical judgment.Keywords: chronic kidney disease, nutrition, phosphate, phosphate binders

Keywords

• chronic kidney disease
• nutrition
• phosphate
• phosphate binders